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Abstract
Background: Physicians of the Spanish Influenza Sentinel Surveillance System report and systematically swab
patients attended to their practices for influenza-like illness (ILI). Within the surveillance system, some Spanish
regions also participated in an observational study aiming at estimating influenza vaccine effectiveness (cycEVA
study). During the season 2009-2010, we estimated pandemic influenza vaccine effectiveness using both the
influenza surveillance data and the cycEVA study.
Methods: We conducted two case-control studies using the test-negative design, between weeks 48/2009 and 8/
2010 of the pandemic season. The surveillance-based study included all swabbed patients in the sentinel
surveillance system. The cycEVA study included swabbed patients from seven Spanish regions. Cases were
laboratory-confirmed pandemic influenza A(H1N1)2009. Controls were ILI patients testing negative for any type of
influenza. Variables collected in both studies included demographic data, vaccination status, laboratory results,
chronic conditions, and pregnancy. Additionally, cycEVA questionnaire collected data on previous influenza
vaccination, smoking, functional status, hospitalisations, visits to the general practitioners, and obesity. We used
logistic regression to calculate adjusted odds ratios (OR), computing pandemic influenza vaccine effectiveness as
(1-OR)*100.
Results: We included 331 cases and 995 controls in the surveillance-based study and 85 cases and 351 controls in
the cycEVA study. We detected nine (2.7%) and two (2.4%) vaccine failures in the surveillance-based and cycEVA
studies, respectively. Adjusting for variables collected in surveillance database and swabbing month, pandemic
influenza vaccine effectiveness was 62% (95% confidence interval (CI): -5; 87). The cycEVA vaccine effectiveness was
64% (95%CI: -225; 96) when adjusting for common variables with the surveillance system and 75% (95%CI: -293; 98)
adjusting for all variables collected.
Conclusion: Point estimates of the pandemic influenza vaccine effectiveness suggested a protective effect of the
pandemic vaccine against laboratory-confirmed influenza A(H1N1)2009 in the season 2009-2010. Both studies were
limited by the low vaccine coverage and the late start of the vaccination campaign. Routine influenza surveillance
provides reliable estimates and could be used for influenza vaccine effectiveness studies in future seasons taken
into account the surveillance system limitations.
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In April 2009, Spain reported the first case of pandemic
influenza A(H1N1)2009 infection in Europe [1] and
since then the pandemic virus activity was monitored by
the Spanish Influenza Sentinel Surveillance System
(SISSS). The system has been in place since 1996 [2] to
provide timely epidemiological and virological informa-
tion on influenza activity in Spain [3] also participating
in the European Influenza Surveillance Network [4]. To
better monitor the pandemic influenza, the 17 Spanish
regional sentinel networks integrated in the surveillance
system increased the number of sentinel general practi-
tioners and paediatricians participating in influenza sur-
veillance and introduced systematic swabbing of
patients.
Annually, in Spain, seasonal influenza vaccination is
recommended to high risk groups for influenza compli-
cations: patients with chronic conditions over six month
old, health care workers, and the elderly [5]. The seasonal
influenza vaccine 2008-2009 showed no effect in prevent-
ing the pandemic influenza A(H1N1)2009 infection [6].
However, the routine vaccination campaign was con-
ducted between September and November 2009 using a
seasonal vaccine [7] similar to the 2008-2009 one.
The pandemic vaccination campaign started on 16
November 2009 (week 46/2009) and continued over the
season using the World Health Organization recom-
mended pandemic monovalent vaccine based on A/Cali-
fornia/7/09-like virus [8]. The vaccine was recommended
for health professionals, essential services, any person
over six month old with chronic conditions (heart dis-
eases, pulmonary diseases (including asthma), renal, liver,
metabolic, neuromuscular, and immune diseases), mor-
bidly obese, pregnant women, and close contacts of high
risk groups [9]. Various vaccine brands were used, mainly
adjuvanted in most of the risk groups and non-adju-
vanted in pregnant women and children.
Since the season 2008-2009, Spain has been participat-
ing in the European Centre for Disease Prevention and
C o n t r o l( E C D C )f u n d e dp r o j e c t“Influenza-Monitoring
of Vaccine Effectiveness” (I-MOVE) [10], aimed at iden-
tifying the best method to estimate influenza vaccine
effectiveness in the European Union (EU). As part of
the I-MOVE project, different designs were piloted
among elderly population, to identify the best approach
to estimate influenza vaccine effectiveness in Spain
(cycEVA study). The test negative design comparing the
vaccination status of the laboratory confirmed cases to
that of patients testing negative for influenza was con-
sidered feasible and adequate for Spain, in the context
of a pandemic [11].
The routine surveillance system has been previously
used [12-14] to estimate the effectiveness of seasonal
vaccine against the circulating influenza strain, using the
test-negative design. It was considered that when suffer-
ing an episode of influenza like illness (ILI), the test
negative controls consult sentinel physicians in the same
way as the influenza laboratory confirmed cases, redu-
cing the bias related to health seeking behaviour [15,16].
We aimed to estimate the pandemic influenza vaccine
effectiveness (PIVE) against laboratory confirmed pan-
demic influenza A(H1N1)2009 infection using both the
surveillance dataset and the cycEVA study, in order to
explore the capacity of surveillance system to provide
annually estimates of influenza vaccine effectiveness in
Spain.
Methods
Using the case-control test-negative design during the
influenza season 2009-2010, we analysed the influenza
surveillance data (surveillance-based study) and we con-
ducted an observational study (cycEVA) embedded in
the surveillance system, collecting more information in a
better controlled way. We describe the two studies
below.
Surveillance-based study
A total of 647 general practitioners and 220 paediatri-
cians from 17 out of 19 Spanish regions participated in
the influenza sentinel surveillance system during the
2009-2010 season, covering 2.6% of the Spanish popula-
tion. Sentinel physicians systematically swabbed the first
two patients presenting with ILI each week. A case defi-
nition based on the EU ILI definition [17] was recom-
mended for patient swabbing as follows: sudden onset
of symptoms, and at least one systemic symptom (fever
or feverishness, malaise, headache, myalgia), and at least
one respiratory symptom (cough, sore throat, shortness
of breath), and in the absence of other suspected clinical
diagnoses.
In the vaccine effectiveness study, we included all
patients with available laboratory results and vaccination
status recorded in the surveillance system during the
study period. Cases were patients laboratory confirmed
for pandemic influenza A(H1N1)2009 virus. Controls
were patients testing negative for any influenza virus
(test-negative controls).
Variables collected for surveillance purpose included:
age, sex, clinical symptoms, date of symptom onset, date
of swabbing, vaccination status for both pandemic and
seasonal vaccines, and laboratory data (confirmation,
influenza type/subtype, strain). For the first time, surveil-
l a n c ed a t aa l s oi n c l u d e di n f ormation on clinical symp-
toms, chronic conditions and pregnancy. Patients were
defined as having at least one chronic disease if they suf-
fered from one of the following conditions: diabetes mel-
litus, cardiovascular diseases, chronic pulmonary
diseases, and congenital or acquired immunodeficiency.
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as a dichotomous variable (yes/no). Data were reported
weekly by each sentinel physician to the Spanish region
epidemiology unit and included into a web-based appli-
cation (http://vgripe.isciii.es/gripe).
cycEVA study
Seven out 17 Spanish regions participated in this study.
We invited all 304 sentinel physicians from these
regions and 235 (77%) agreed to participate. The popu-
lation covered by these sentinel physicians represented
2.0% of the total population of the seven Spanish
regions.
The 235 study sentinel physicians also participated in
the influenza surveillance system and systematically
swabbed patients throughout the study period. The defi-
nition of cases and controls was the same as in the sur-
veillance-based study. Thus, cases and controls of
cycEVA study were also included in the surveillance-
based study.
Using a standardised questionnaire, the participating
physicians collected in addition to surveillance data (see
above) the following variables: date of vaccination, influ-
enza vaccination in the two previous seasons, smoking,
functional status, obesity, hospitalisations for chronic
conditions, and outpatient visits in the previous 12
months. “Any chronic condition” variable was defined
the same as in the surveillance-based study. We defined
obesity (body mass index over 30) and pregnancy as risk
factors for pandemic influenza. The low functional sta-
t u sw a sd e f i n e da sn e e do fh e l pf o rb a t h i n go rw a l k i n g .
A patient was considered vaccinated if he/she had
received the pandemic influenza vaccine 14 days or
more before the date of symptom onset. Vaccination
status was verified against the vaccination registry and/
or the patient clinical history available at sentinel physi-
cians’ offices.
We excluded from the cycEVA study: patients who
refused to participate; those not eligible for influenza
vaccination because they suffered from a condition listed
in the summary of product characteristics; institutiona-
lised patients; those unable to give informed consent or
having received antiviral treatment at the moment of
swabbing.
In both studies, we included in the analysis all
swabbed patients with less than eight day delay between
symptom onset and swabbing and who were attended
by sentinel physicians two weeks after the start of the
pandemic vaccination campaign (week 48/2009) up to
week 8/2010 when the last confirmed influenza A
(H1N1)2009 case was reported to cycEVA study. In a
subsequent stage, we restricted the analysis to patients
meeting the EU ILI case definition. We also estimated
the pandemic vaccine effectiveness restricting the
analysis to patients with less than four day delay
between the symptom onset and swabbing to avoid mis-
classification due to period of viral shedding.
We calculated the crude and adjusted odds ratios
(OR) and their corresponding 95% confidence intervals
(95% CI) using logistic regression. We included in the
logistic regression models all variables available and
known from the literature to influence the influenza
vaccine effectiveness estimates as well as the month of
swabbing. Thus, the model for the surveillance-based
study included: age group, sex, seasonal vaccination,
chronic conditions, pregnancy, and month of swabbing.
In the cycEVA study, we first adjusted for the variables
common to both studies and then we included the addi-
tional covariates collected as well as the month of swab-
bing (full model). We computed PIVE as (1-OR)*100.
STATA/IC 10 was used for all statistical analyses (Stata
Statistical Software: Release 10. StataCorp LP, TX, USA).
The network-affiliated laboratories or the National
Centre of Microbiology (WHO National Influenza Cen-
tre) confirmed influenza cases using real-time polymer-
ase chain reaction (PCR) or culture on Madin-Darby
canine kidney (MDCK) cell lines. For a proportion of
laboratory confirmed cases amplified products were
sequenced at the National Centre of Microbiology. Phy-
logenetic analysis was done to identify the influenza A
(H1N1)2009 virus.
Both studies were carried out in the frame of the
existing Spanish Influenza Sentinel Surveillance System
at the National Centre of Epidemiology; no ethical
approval is required for surveillance activities in Spain.
However, no personal data were collected and patients
gave verbal consent to be swabbed. The cycEVA study
was carried out following a generic protocol developed
for ECDC [18] and adapted for Spain by the National
Centre of Epidemiology.
Results
In Spain, the pandemic influenza activity exceeded the
baseline level in the week 40/2009 reaching the peak in
the week 46/2009 (372 ILI cases/100,000 inhabitants)
(Figure 1). The epidemic period lasted for 11 weeks,
from week 40/2009 to week 50/2009. The highest inci-
dence was recorded in the age group 5-14 years old
(cumulative incidence: 7507 ILI cases/100,000 inhabi-
tants). The maximum influenza weekly incidence in this
age group was 1104 ILI cases/100,000 inhabitants in the
epidemic peak.
Surveillance-based study
From week 48/2009 to week 8/2010, sentinel physi-
cians notified 4580 ILI cases of which 1909 (42%) were
swabbed. After excluding patients with no laboratory
results (160 records), those with influenza type B or C
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able subtype (seven records), 425 pandemic influenza
A(H1N1)2009 cases were recorded. The pandemic vac-
cination status was available for 1413 (74%) patients.
We included in the analysis the 1326 patients swabbed
less than eight days after the symptom onset: 331
influenza A(H1N1)2009 cases and 995 test-negative
controls. The number of recruited pandemic influenza
cases decreased by week of swabbing during the study
period (Figure 1). Cases and test-negative controls did
not differ by patient characteristics available in the sur-
veillance system, except for clinical symptoms. Cases
were more likely to present with sudden onset, fever,
malaise, headache, cough and sore throat than con-
trols. Nine cases (2.7%) and 41 controls (4.1%) were
vaccinated with the monovalent pandemic vaccine
(Table 1).
The crude pandemic influenza vaccine effectiveness
was 35% (95% CI: -38; 73) and the adjusted value was
62% (95% CI: -5; 87). We obtained similar results in the
analysis restricted to patients with a delay symptom
onset-swabbing less than four days (Table 2). The
adjusted point estimates using patients complying with
the EU ILI case definition was 41% (95% CI: -95; 82).
When we additionally restricted the analysis to ILI
patients swabbed in less than four days since the symp-
tom onset, adjusted PIVE was 48% (95% CI: -110; 82)
(Table 2).
cycEVA study
A total of 440 ILI patients were recruited between week
48/2009 and week 8/2010. After excluding cases con-
firmed for other influenza viruses (one case type B),
those with a delay between symptom onset and swab-
bing of more than seven days (three records), we
included in the analysis 436 ILI cases: 85 influenza A
(H1N1)2009 cases and 351 test-negative controls. The
number of recruited patients decreased during the study
period (Figure 2). Most of the patients (62%) were
recruited towards the end of the epidemic period (week
48-50/2009). Cases and test-negative controls were simi-
lar for most variables included in the study. Among
cases, 92.7% presented cough compared to 80.7% con-
trols (Table 3).
We identified two (2.4%) cases and 19 (5.4%) controls
vaccinated with the monovalent pandemic vaccine. The
crude PIVE was 58% (95% CI:-81; 95) and that adjusted
for all covariates was 75% (95% CI:-293; 98). The PIVE
adjusted for the covariates available in surveillance sys-
tem was 65% (95%CI: -221; 96). We obtained similar
results in the analysis restricted to patients with a delay
between symptom onset and swabbing less than four
days (Table 2). Using the cases that complied with the
EU ILI case definition, the adjusted PIVE for all covari-
ates was 71% (95%CI: -402; 98) and 59% (95%CI: -300;
96) when adjusting for the covariates common to both
studies. PIVE estimates in the restricted analysis to a
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Figure 1 Surveillance-based study ILI cases (N = 1326) and ILI incidence at national level, season 2009-2010, Spain. Pandemic influenza
laboratory positive cases (red), laboratory negative controls (grey grid) and Influenza-like illness incidence per 100,000 inhabitants at national
level (blue line) by week of swabbing in the surveillance-based study.
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among those that complied to the EU ILI case definition
were 72% (95%CI: -290; 99) using the full model and
68% (95%CI: -215; 97) adjusting for covariates available
in the surveillance system (Table 2).
Laboratory findings
Among the 331 influenza A(H1N1)2009 cases reported
to the surveillance system during the study period, 66
(20%) were genetically characterised. In the cycEVA
study, 68 (80%) specimens were sent for genetic
Table 1 Characteristics of influenza laboratory confirmed cases (n = 331) and test-negative controls (n = 995) in the
surveillance-based study
a, season 2009-2010, Spain
Characteristics Cases
n (%)
ILI negative controls
n (%)
p value
b
Mean age (SD
c) 23.4 (17.8) 25.4 (21.4) 0.125
Sex: male 162/330 (49.1) 492/984 (50.0) 0.775
Pandemic influenza vaccination 9/331 (2.7) 41/995 (4.1) 0.234
Seasonal influenza vaccination 37/330 (11.2) 104/988 (10.5) 0.727
Symptoms:
▪ sudden onset 211/241 (87.5) 562/817 (68.8) < 0.0001
▪ fever 321/328 (97.9) 890/991 (89.8) < 0.0001
▪ malaise 268/315 (85.1) 713/967 (73.7) < 0.0001
▪ headache 251/320 (78.4) 588/964 (61.0) < 0.0001
▪ myalgia 213/322 (66.2) 589/978 (60.2) 0.057
▪ cough 295/329 (89.7) 775/985 (78.7) < 0.0001
▪ sore throat 224/322 (69.6) 601/970 (61.9) 0.013
▪ shortness of breath 27/305 (8.9) 84/948 (8.9) 0.996
At least one chronic condition 39/247 (15.8) 120/826 (14.5) 0.624
Pregnancy 5/329 (1.5) 7/976 (0.7) 0.187
Complying with EU case definition 195/331 (58.9) 506/995 (50.8) 0.011
Delay onset-swabbing less than four days 301/331 (90.9) 874/995 (87.8) 0.124
a Cases and controls recruited between week 48/2009 and week 8/2010, and with a delay symptom onset-swabbing less than eight days;
b Chi-square or Fisher
exact test when appropriate;
c SD-standard deviation.
Table 2 Pandemic influenza vaccine effectiveness in the surveillance-based and cycEVA studies
a, season 2009-2010,
Spain
Surveillance-based study cycEVA study
Included population N PIVE % (95%CI
b) N PIVE % (95%CI
b)
Crude All patients 1326 35 (-38; 73) 436 58 (-81; 95)
▪ Delay onset-swabbing less than four days 1175 35 (-45; 74) 381 57(-87; 95)
EU case definition 701 14 (-131; 72) 377 53 (-109; 95)
▪ Delay onset-swabbing less than four days 627 5 (-161; 70) 336 64 (-104; 95)
Adjusted models All patients
▪ full model
c 301 75 (-293; 98)
▪ SISSS covariates
d 993 62 (-5; 87) 351 65 (-221; 96)
All patients and delay onset-swabbing less than four days
▪ full model
c 258 77 (-296; 98)
▪ SISSS covariates
d 853 58 (-21; 85) 302 67 (-211; 97)
EU case definition
▪ full model
c 255 71 (-402; 98)
▪ SISSS covariates
d 644 41 (-95; 82) 299 59 (-300; 96)
EU case definition and delay onset-swabbing less than four days
▪ full model
c 231 72 (-290; 99)
▪ SISSS covariates
d 568 48 (-110; 82) 263 68 (-215; 97)
a Cases and controls recruited between week 48/2009 and week 8/2010 and with a delay symptom onset-swabbing less than eight days;
b CI = confidence
interval;
c Adjusted for age group, sex, seasonal vaccination, chronic conditions, previous hospitalizations, number of GP visits in the previous year, functional
status, smoking, previous influenza vaccination, risk factors for pandemic influenza, and month of swabbing;
d Adjusted for age group, sex, seasonal vaccination,
chronic conditions, pregnancy, and month of swabbing; SISSS = Spanish Influenza Sentinel Surveillance.
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genetic material for the test to be performed. Sequence
analysis of the product of amplification (948 nucleotides
of the HA1 fragment of the hemagglutinin gene) showed
that all the pandemic influenza A strains studied were
similar to the vaccine strain A/California/07/2009.
Discussion
Our results showed a possible protective effect of the
pandemic vaccine against medically attended laboratory
confirmed pandemic influenza A(H1N1)2009 in Spain,
in the context of low vaccination coverage and low ILI
incidence at the end of the epidemic period when the
study was carried out. However, these results are consis-
tent with the good matching between the vaccine and
circulating strains.
Only a few vaccine failures were recorded in both stu-
dies. Pandemic vaccination started during the epidemic
peak in the week 46/2009, leaving only a short period of
time to enable vaccine effectiveness studies (after week
48/2009). In addition, the vaccination coverage was
lower than expected, reaching 16% in the target groups
for vaccination at the national level [19]. The pandemic
vaccination coverage in the sentinel physicians’ catch-
ment area of the seven participating networks was
10.7%. This made difficult to estimate with precision the
PIVE in both studies.
We adjusted for most of the confounders described in
the literature in the cycEVA study and for available con-
founders in the surveillance-based study. The covariates
that mainly influenced the results (more than 5% differ-
ence between the crude and Mantel-Haenszel adjusted
OR) were: chronic conditions and seasonal vaccination
2009-2010 for the surveillance-based study and age, sex,
chronic conditions, month of swabbing, functional sta-
tus, at least one hospitalisation in the previous 12
months, and GP visits in the previous 12 months for the
cycEVA study (data not shown). cycEVA PIVE estimates
using the full model were around 10% higher than the
PIVE adjusted only for the variables collected in surveil-
lance system. When adjusting for the common variables
in the surveillance-based and cycEVA studies, the PIVE
point estimates were similar for all patients. Restricting
the analysis to a delay symptom onset -swabbing less
than four days or to patients meeting EU case definition,
the PIVE was around 10-20% higher in the cycEVA
study, probably reflecting the better data collection in
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Figure 2 cycEVA study ILI cases (N = 436) and ILI incidence in
the participating regions, season 2009-2010, Spain. Pandemic
influenza laboratory positive cases (red), laboratory negative controls
(grey grid) and Influenza-like illness incidence per 100,000
inhabitants in the seven participating Spanish regions (blue line) by
week of swabbing in the cycEVA study.
Table 3 Characteristics of influenza laboratory confirmed
cases (n = 85) and test-negative controls (n = 351) in the
cycEVA study
a, season 2009-2010, Spain
Characteristics Cases
n (%)
Controls
n (%)
p
value
b
Mean age (SD
c) 33.2 (17.9) 35.9 (20.0) 0.256
Sex: male 34/85
(40.0)
174/350
(49.7)
0.108
Pandemic influenza vaccination 2/85 (2.4) 19/351 (5.4) 0.395
Seasonal influenza vaccination 9/84
(10.7)
45/347
(12.9)
0.714
Symptoms:
▪ sudden onset 80/84
(95.2)
322/342
(94.2)
0.699
▪ fever 83/84
(98.8)
321/337
(95.3)
0.138
▪ malaise 77/79
(97.5)
305/317
(96.2)
0.589
▪ headache 70/78
(89.7)
254/310
(81.9)
0.097
▪ myalgia 63/79
(79.8)
275/316
(87.0)
0.100
▪ cough 76/82
(92.7)
268/332
(80.7)
0.010
▪ sore throat 58/81
(71.6)
239/315
(75.9)
0.429
▪ shortness of breath 9/74
(12.2)
23/266 (8.6) 0.371
Previous vaccination 9/78
(11.5)
45/300
(15.0)
0.586
Smoking 3/72 (4.2) 18/277 (6.5) 0.586
Any hospitalization 2/75 (2.7) 5/279 (1.8) 0.643
GP visits > eight in the previous
year
16/74
(21.6)
68/282
(24.1)
0.653
Any chronic conditions 6/83 (7.2) 53/332
(15.9)
0.052
Pregnancy and obesity 7/84 (8.3) 26/348 (7.5) 0.819
Poor functional status 1/80 (1.3) 18/337 (5.3) 0.143
Complying with EU case definition 77/85
(90.6)
300/351
(85.5)
0.215
Delay onset-swabbing less than four
days
80/85
(94.1)
301/351
(85.8)
0.037
a Cases and controls recruited between week 48/2009 and week 8/2010 and
with a delay symptom onset-swabbing less than eight days;
b Chi square or
Fisher exact tests when appropriate;
c SD-standard deviation.
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dies are lower than those reported by other authors
[20-24]. The differences may be related either to the dif-
ferent outcomes and study designs or to the different
confounding factors adjusted for. A European multicen-
tre study (I-MOVE) in which Spain participated with
data from the cycEVA study confirmed the cycEVA esti-
mates by pooling data from seven countries [25].
The results of both studies suggest the presence of
negative confounding [26], because the adjusted point
estimates were higher than the crude ones. When we
measured the effectiveness of the seasonal vaccine dur-
ing the previous influenza season [6,11], the adjusted VE
estimates were lower than the crude VE, suggesting the
predominance of positive confounding. Because the
Spanish population consults GPs more often than the
EU average (outpatient contacts/person/year 9.5 in 2003
in Spain and 7.67 in the EU) [27], we believe this
increases the probability that more elderly people with
better functional status are attended by the sentinel phy-
sicians (healthy vaccinee effect). This was not the case
during the 2009-2010 season. The observed negative
confounding might be related to the dynamics of the
influenza activity and/or to different health seeking
behaviour during the pandemic in Spain. Further studies
are needed in the future influenza seasons to better
understand these findings.
Among the limitations of the surveillance-based study,
we should also mention the lack of collecting of the
pandemic vaccination date. Unlike the usual influenza
seasons when the vaccination campaign complete before
the epidemic period, the pandemic vaccination started
and was carried out during the pandemic wave. In this
context, determining the delay between vaccination and
symptom onset became of crucial importance because
some individuals classified as vaccinated may not have
been protected, resulting in an underestimation of the
vaccine effectiveness. However, 80% of pandemic vacci-
nations were performed in the first two weeks of the
campaign [source: Ministry of Health and Social Poli-
cies, Spain, unpublished data]. Restricting the study per-
iod to two weeks after the start of the vaccination
campaign might have reduced this misclassification in
the surveillance-based study.
As it was impossible to distinguish the cycEVA
patients in the surveillance database, we were not able
to compare cycEVA patients to the rest of the surveil-
lance system. However, subtracting the Spanish regions
participating in cycEVA from the total number of
patients included in the surveillance study, the crude
OR was 0.83 (95%CI: 0.29; 2.04), resulting in a crude
pandemic vaccine effectiveness of 17%. This might be
related to a lower compliance to the EU ILI case defini-
tion in the rest of the surveillance system compared to
cycEVA or to a higher weighting given to the clinical
judgement during the pandemic season due to the addi-
tional statement “in the absence of other suspected clin-
ical diagnoses” added to EU ILI case definition. In fact,
sentinel physicians participating in the cycEVA study
used the mentioned EU ILI case definition since the sea-
son 2008-2009, meanwhile the rest of surveillance sys-
tem adopted it for the pandemic 2009-2010 season. This
was only revealed collecting the clinical symptoms in
the surveillance system which allowed estimating the
compliance with the EU ILI case definition. We also
f o u n dt h a tm o r et h a n4 0 %o fi n fluenza laboratory con-
firmed cases notified to the surveillance system did not
meet the EU ILI case definition (low sensitivity), sug-
gesting that the clinical judgement of the sentinel physi-
cians might be useful for the recruitment of true
positive cases. These findings underline the need for
further studies related to EU ILI case definition.
The well established influenza sentinel surveillance
system in Spain rapidly adapted to monitor pandemic
influenza and allowed studying different aspects of its
activity, including vaccine effectiveness. Data were
weekly notified and analysed at regional and central
level. Several improvements were implemented in the
surveillance system for the pandemic season: data col-
lection was expanded to include clinical symptoms,
chronic conditions and pregnancy; systematic swabbing
was introduced. On the other hand, cycEVA study pre-
sented an added value for the surveillance system.
Firstly, additional information was collected on con-
founding factors known from the literature to influence
influenza vaccine effectiveness estimates. Secondly, col-
lecting the date of vaccination allowed avoiding misclas-
sification of those vaccinated but not protected, which
proved to be essential during the pandemic season. Last
but not least, the data collection in the cycEVA study
was more complete and periodically validated.
Conclusions
The sentinel influenza surveillance system in Spain
allowed estimating the pandemic influenza vaccine effec-
tiveness during a season with a high sentinel physicians’
workload. The results of both studies suggested a possi-
ble protective effect of the vaccine against laboratory
confirmed influenza A(H1N1)2009 infection, higher
when vaccination date is collected and some important
confounding factors are taking into account. This sug-
gests that the routine influenza surveillance system pro-
vides reliable estimates and could be used for influenza
vaccine effectiveness estimates, if the data collection is
improved by taking into account the date of vaccination
and some additional potential confounding factors.
The pandemic season 2009-2010 represented a chal-
lenge for vaccine effectiveness studies due to the
Savulescu et al. BMC Public Health 2011, 11:899
http://www.biomedcentral.com/1471-2458/11/899
Page 7 of 9availability of the vaccine after the pandemic peak and
the low pandemic influenza vaccination coverage.
Repeating both studies in future seasons and using
cycEVA study as a validation subset of the whole sur-
veillance system will provide further information to
draw conclusions on the effectiveness of the influenza
vaccination in Spain.
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